Business Context and Reporting Period
This Form 8-K reports on the 2017 Annual Meeting of Stockholders held by Imprimis Pharmaceuticals, Inc. on June 13, 2017. The meeting took place at the San Diego Marriott Del Mar Hotel. The filing was signed by Andrew R. Boll, Chief Financial Officer, on June 16, 2017. Note: The request metadata references "Harrow, Inc.," but the filing text explicitly identifies the registrant as Imprimis Pharmaceuticals, Inc.
Key Financial Metrics
This filing is a Current Report regarding corporate governance events and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Three proposals were submitted to a binding vote of stockholders, and all were approved. A total of 19,965,415 shares were entitled to vote, with 15,025,849 shares present or represented by proxy.
- Proposal 1: Election of Directors
- Five nominees were elected to serve until the 2018 annual meeting.
- Stephen G. Austin: 7,319,390 For; 1,793,002 Withheld.
- Mark L. Baum: 8,383,693 For; 728,699 Withheld.
- Robert J. Kammer: 7,362,623 For; 1,749,769 Withheld.
- Richard L. Lindstrom: 7,296,997 For; 1,815,395 Withheld.
- Anthony J. Principi: 8,086,228 For; 1,026,164 Withheld.
- Broker non-votes totaled 5,913,457 for all director nominees.
- Proposal 2: Ratification of Auditors
- Stockholders ratified KMJ Corbin and Company, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017.
- Results: 14,736,566 For; 167,394 Against; 121,889 Abstain.
- Proposal 3: Approval of 2017 Incentive Plan
- Stockholders approved the 2017 Incentive Stock and Awards Plan.
- Results: 6,544,464 For; 2,405,375 Against; 162,553 Abstain.
- Broker non-votes totaled 5,913,457.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It is limited to the reporting of voting outcomes and the submission of exhibits related to the new incentive plan.
Important Facts for Investors to Verify
- Verify the identity of the registrant as Imprimis Pharmaceuticals, Inc. (not Harrow, Inc.) to ensure correct entity tracking.
- Confirm the terms of the newly approved 2017 Incentive Plan by reviewing the attached exhibits (10.1 through 10.4) regarding stock options and restricted stock units.
- Note the significant number of broker non-votes (5,913,457) on the director election and incentive plan proposals, indicating shares held by brokers that were not voted on these discretionary matters.
- Review the 2017 Annual Report (10-K) for the actual financial performance data, as this 8-K contains no financial metrics.